ABEONA THERAPEUTICS INC (ABEO) Stock News

USA - Nasdaq - NASDAQ:ABEO - US00289Y2063 - Common Stock

5.07 USD

-0.08 (-1.55%)

Last: 11/28/2025, 8:11:22 PM

5.07 USD

0 (0%)

After Hours: 11/28/2025, 8:11:22 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ABEO Latest News, Press Relases and Analysis

All

Press Releases

18 days ago - By: Chartmill - Mentions: FMFC NTWK PAL BKYI ...

News Image

Keep an eye on the top gainers and losers in Wednesday's session.

18 days ago - By: Chartmill - Mentions: FMFC GTI NTWK PAL ...

News Image

There are notable gap-ups and gap-downs in today's session.

18 days ago - By: Benzinga - Mentions: IRIX SI LUCY SLRX ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

18 days ago - By: The Motley Fool - Mentions: CI AET

Here's Why Abeona Therapeutics Popped Higher Today

18 days ago - By: Chartmill

News Image

Abeona Therapeutics (NASDAQ:ABEO) Stock Falls on Revenue Miss Despite Q3 EPS Beat

18 days ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

18 days ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

19 days ago - By: Benzinga

What to Expect from Abeona Therapeutics's Earnings

23 days ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

23 days ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

a month ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)

a month ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)

a month ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

a month ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

2 months ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program

2 months ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program

2 months ago - By: Abeona Therapeutics Inc.; Children's Hospital of Colorado

Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy

2 months ago - By: Abeona Therapeutics Inc.; Children's Hospital of Colorado

Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy

2 months ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

3 months ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

4 months ago - By: The Motley Fool

Abeona Posts Q2 Profit on Asset Sale

4 months ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

4 months ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

4 months ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: AscellaHealth, LLC

AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients

5 months ago - By: Abeona Therapeutics Inc.

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

5 months ago - By: Abeona Therapeutics Inc.

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

5 months ago - By: Bio-Techne Corporation - Mentions: TECH

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

5 months ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

5 months ago - By: Abeona Therapeutics Inc.

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million